



New perspectives in early diagnosis and HIV co-infection :The Spanish Strategic Plan for Prevention and Control of HIV and STIs, 2013 - 2016

Elena Andradas Aragonés

Deputy-Director of Health Promotion and Epidemiology- National AIDS Strategy






HIV epidemic, Spain 2013


| People living with HIV | 150,000 (130,000-170,000) |
|--------------------------------------|------------------------------|
| HIV prevalence | 0.4% |
| Total AIDS cases (30 Jun 2014) | 84,043 |
| Deaths in HIV/AIDS cases (1981-2012) | 56,079 |
| New HIV Diagnoses (rate/100000) | 10.3 |

| New HIV diagnoses | | People living with HIV | | |
|-------------------------|-------|-------------------------|-------|--|
| Transmission mode | | Transmission mode | | |
| People who inject drugs | 4.4% | People who inject drugs | 37,8% | |
| MSM | 51,2% | MSM | 25,2% | |
| Heterosexuals | 28.5% | Heterosexuals | 28,9% | |

Sources: Estimates performed with EPP/Spectrum, SINIVIH, AIDS registry, National Mortality Statistics, Encuesta Hospitalaria









GOBERNO DE ESPAÑA





Late presentation by sex. New HIV diagnoses. Spain, 2013.





n = 398




Late presentation He New HIV diagnoses. Spain, 2013.



Late presentation by transmission mode

Late presenters by transmission mode

n=1,284







Advanced HIV disease/late presentation in new HIV diagnoses. Spain, 2007-2011


| | Advanced HIV dise | ase (<200 cell /µL)* | Late presentation (<350 cell /µL)* | |
|--------------------|-------------------|----------------------|------------------------------------|-----------|
| Characteristics | Adjusted OR | 95% CI | Adjusted OR | 95% CI |
| Sex | | | | |
| Female | 1 | | 1 | |
| Male | 1.3 | [1.1-1.5] | 1.4 | [1.2-1.5] |
| Age (years) | | | | |
| 0-19 | 0.4 | [0.3-0.7] | 0.5 | [0.3-0.7] |
| 20-29 | 1 | | 1 | |
| 30-39 | 1.7 | [1.5-1.9] | 1.4 | [1.2-1.5] |
| 40-49 | 2.8 | [2.5-3.2] | 2.2 | [2.0-2.5] |
| ≥50 | 4.4 | [3.8-5.1] | 3.3 | [2.9-3.8] |
| Transmission mode | | | | |
| MSM | 1 | | 1 | |
| PWID | 2.0 | [1.7-2.4] | 1.9 | [1.6-2.2] |
| Hetero | 2.4 | [2.1-2.7] | 2.1 | [1.9-2.4] |
| Region of origin | | | | |
| Spain | 1 | | 1 | |
| Western Europe | 1.1 | [0.9-1.3] | 1.1 | [0.9-1.3] |
| Eastern Europe | 1.7 | [1.3-2.1] | 1.3 | [1.1-1.7] |
| Latin America | 1.4 | [1.3-1.6] | 1.6 | [1.5-1.8] |
| Sub-Saharan Africa | 1.4 | [1.2-1.7] | 1.7 | [1.5-2.0] |
| North Africa | 1.6 | [1.1-2.4] | 1.5 | [1.0-2.1] |

Model adjusted by year of diagnosis





Prevalence of Hepatitis C virus (PCR+) in HIV-infected patients. Spain, 2004–2013




Source: Encuesta hospitalaria de pacientes infectados con VIH (EH) (Annual one-day cross-sectional survey on PLWH attending hospitals)






Prevalence of Hepatitis C virus (PCR+) among HIVinfected patients, by sex. Spain, 2004–2013







Patients with HIV-HCV co-infection on treatment. Spain, 2004–2013





35

30

25

20

15

10

5

0

2002

'n

Α

Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

Dead Alive



J. M. Miro^{a,*}, M. Montejo^b, L. Castells^{c,d}, A. Rafecas^e, S. Moreno^f, F. Agüero^a, M. Abradelo^g, P. Miralles^h, J. Torre-Cisnerosⁱ, J. D. Pedreira^j, E. Cordero^k, G. de la Rosa^l, B. Moyano^m, A. Moreno^a, I. Perez^a, A. Rimola^{a,d} and the Spanish OLT in HIV-Infected Patients Working Group investigators†

Figure 1. (A) Annual number of liver transplants in HCV/HIV-coinfected patients performed in Spain between 2002 and 2006. (B) Number of liver transplants performed in HCV/HIVcoinfected patients in the 17 participating centers.

In conclusion, OLT is an effective short-term procedure in HCV/HIV-coinfected recipients. Patient and graft survival in the medium term were lower than that of the matched HCV-monoinfected patients, although it remained acceptable. Our study was able to identify subsets of patients with a more favorable prognosis. Liver transplantation in HCV/HIV-coinfected patients restricted to sites with more experience and better anti-HCV therapies could improve long-term outcome in these patients.


2004

Years of transplantation

2005

American Journal of Transplantation 2012; 12: 1866–1876 Wiley Periodicals Inc.


2003







2013: The Introduction of IFN-Free HCV Therapy



Current status of sofosbuvir in Spain



- **Sofosbuvir** was approved by the EMA in January 2014
- Spanish Health Minister, Ana Mato, announced last week the finalization of the approval procedure in Spain
- Spanish Drug and Health Products Agency in collaboration with the Autonomous Regions and Scientific Societies has developed a therapeutic positioning report
- This report is based on the available clinical and scientific Knowledge and to make up a guideline to be used by institutions and healthcare professionals





STRATEGIC PLAN FOR PREVENTION AND CONTROL OF HIV AND OTHER SEXUALLY TRANSMITTED INFECTIONS 2013-2016

National Committee of Coordination and Monitoring on AIDS Prevention Programmes 19th Diciembre 2013.







Coordination of the epidemic response

Promoting health and preventing infection

- □ Improving health results
- Guarantee community access



Objectives



- Reducing the incidence of HIV infection and other STI
- Promoting the early diagnosis of HIV and other STI.
- Improving the quality of life of patients and prevent associated comorbidity
- Reducing discrimination against people with HIV and STIs



Promoting early diagnosis of HIV and other STI - I



- 1. Promoting early diagnosis:
 - Guideline for early diagnosis in Healthcare settings
 - Elaborating a guideline for early diagnosis for Community settings
 - Developing a protocol to implement the Guideline in Health Care settings
 - Studying the feasibility and acceptabillity of the responsible use of hometesting
 - Promoting early diagnosis for STI, and the performace of the HIV testing in case of STI



Promoting early diagnosis of HIV and other STI - II



- 2. Designing and implementing a community setting information system about early HIV diagnosis
- Elaborating a resource map of community centers performing the test for HIV and other STIs at national level
- 4. Carrying out a protocol for the study of contacts and anonymous treatment of STIs



Guideline for early diagnosis Hep in Healthcare settings



General Objective:

Promoting the early diagnosis of HIV and other STI, to reduce the number of non diagnosed people

General Specific Objectives:

- Promoting HIV testing performance in general porpulation
- Providing specific recommendations for the indication of HIV testing
- Offering information and training to health professionals
- Empowering patients in the decision to get tested.



Guideline for early diagnosis in Healthcare settings




Scope

The Guide is intended to provide information to health professionals and the neccesary active support for conducting HIV testing, both in the field of primary and specialized care in Spain



HIV TESTING ALGORITHM









Thank you

http://www.msssi.gob.es/







